China Pharma Holdings, Inc.
CPHI
$1.50
-$0.0634-4.06%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -47.25% | -39.00% | -15.76% | -30.12% | -26.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -47.25% | -39.00% | -15.76% | -30.12% | -26.41% |
| Cost of Revenue | -41.91% | -20.47% | 55.91% | -6.87% | -22.57% |
| Gross Profit | -102.78% | -122.81% | -592.16% | -263.01% | -285.48% |
| SG&A Expenses | 8.05% | 9.99% | -25.92% | 7.64% | -19.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.12% | -13.17% | 49.05% | -3.05% | -18.48% |
| Operating Income | -0.97% | -52.11% | -204.95% | -130.47% | -1.33% |
| Income Before Tax | 0.63% | -43.76% | -142.51% | -100.82% | 2.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.63% | -43.76% | -142.51% | -100.82% | 2.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.63% | -43.76% | -142.51% | -100.82% | 2.53% |
| EBIT | -0.97% | -52.11% | -204.95% | -130.47% | -1.33% |
| EBITDA | -53.06% | -1,177.30% | -373.50% | -164.55% | 2.59% |
| EPS Basic | 68.62% | 78.04% | 74.58% | 75.29% | 82.77% |
| Normalized Basic EPS | 68.62% | 78.03% | 74.60% | 75.29% | 82.76% |
| EPS Diluted | 68.62% | 78.04% | 74.58% | 75.29% | 82.77% |
| Normalized Diluted EPS | 68.62% | 78.03% | 74.60% | 75.29% | 82.76% |
| Average Basic Shares Outstanding | 216.93% | 554.74% | 854.09% | 712.80% | 465.62% |
| Average Diluted Shares Outstanding | 216.93% | 554.74% | 854.09% | 712.80% | 465.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |